Published in Support Care Cancer on January 25, 2003
A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) (2004) 1.43
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer (2006) 1.41
A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer (2007) 1.27
Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer (2010) 1.01
Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. Breast Cancer (Dove Med Press) (2011) 0.86
2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Support Care Cancer (2016) 0.84
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer (2008) 0.83
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project. Support Care Cancer (2013) 0.82
Antiemetic prescribing practices using a computerized physician order entry system. Support Care Cancer (2013) 0.75
Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The Italian Group for Antiemetic Research. N Engl J Med (2000) 2.70
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med (1999) 2.18
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol (1985) 1.72
Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol (1991) 1.10
Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol (1998) 1.10
Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. J Clin Oncol (1997) 0.89
Delayed emesis following anticancer chemotherapy. Support Care Cancer (1998) 0.86
Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research. Ann Oncol (1997) 0.79
Acute and delayed emesis after cisplatin-based regimen: description and prevention. Oncology (1991) 0.78
The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial. Br J Cancer (1989) 0.75
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med (2004) 8.60
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 4.81
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
Aprepitant for erlotinib-induced pruritus. N Engl J Med (2010) 2.97
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol (2008) 2.40
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist (2008) 2.22
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res (2007) 2.18
Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab (2014) 2.17
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol (2007) 2.08
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res (2006) 2.07
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2011) 2.02
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol (2009) 2.00
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol (2008) 1.99
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst (2008) 1.92
Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol (2012) 1.75
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res (2002) 1.66
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res (2003) 1.61
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol (2007) 1.60
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer (2007) 1.58
Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. BMC Cancer (2010) 1.52
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer (2006) 1.47
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? J Clin Oncol (2006) 1.45
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44
MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients. Cancer Biol Ther (2009) 1.42
Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison. Eur Urol (2006) 1.38
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist (2010) 1.35
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res (2003) 1.34
Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol (2003) 1.34
The biological properties of cetuximab. Crit Rev Oncol Hematol (2008) 1.31
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat (2007) 1.30
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat (2006) 1.29
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol (2011) 1.27
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer (2008) 1.27
HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol (2007) 1.25
Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer (2006) 1.25
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia (2009) 1.23
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol (2013) 1.20
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res (2011) 1.19
Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg (2003) 1.19
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer (2009) 1.18
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer (2009) 1.17
In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother (2008) 1.16
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res (2005) 1.16
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology (2005) 1.15
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia (2009) 1.15
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One (2012) 1.15
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol (2006) 1.14
Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc) (2003) 1.14
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer (2009) 1.13
Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. Int J Cancer (2006) 1.11
The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions. Anticancer Res (2013) 1.11
Testis metastasis as an initial manifestation of an occult gastrointestinal cancer. Anticancer Res (2004) 1.09
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol (2014) 1.09
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat (2007) 1.08
ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica (2011) 1.08
Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. Expert Opin Ther Targets (2013) 1.07
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest (2014) 1.06
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer (2004) 1.04
Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer (2006) 1.04
Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells. Clin Cancer Res (2004) 1.04
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets (2011) 1.03
Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res (2006) 1.02
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology (2009) 1.02
Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol (2010) 1.02
R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol (2007) 1.02
Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade. Mod Pathol (2007) 1.02
Target therapies in pancreatic carcinoma. Curr Med Chem (2014) 1.01
Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev (2006) 1.01
Cerebellar metastasis from pancreatic adenocarcinoma. A case report. Pancreatology (2006) 1.00
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res (2010) 1.00
Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol (2005) 0.99
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer (2008) 0.99
Severe rhabdomyolysis associated with pemetrexed-based chemotherapy. Lancet Oncol (2006) 0.99
Molecular and genetic bases of pancreatic cancer. Curr Drug Targets (2012) 0.98
Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab. J Thorac Oncol (2012) 0.98
White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. Haematologica (2010) 0.98
Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer (2008) 0.97
Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. Support Care Cancer (2007) 0.97
Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biol Ther (2005) 0.97
New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev (2004) 0.97
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis (2007) 0.97
Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol (2006) 0.97
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res (2011) 0.96
Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer (2009) 0.96
A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol (2007) 0.96
TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica (2013) 0.96